The team at Exploristics has an extensive publication record, with a selection of relevant examples listed below.

Speciality Statistics

  1. Watson, L., Farquhar, R., Das, R. and Flynn, A.  Cart analysis as a tool to determine optimal treatment intensification time in diabetes. Value in Health 2015 11;18(7): A682.
  2. Jenkins, R. G. et al., Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective multicentre PROFILE study.  The Lancet Respiratory Medicine 2015 3; 6: 462-472.
  3. Alderton, W. et al., CA19.9 Profiles in Samples Predating Pancreatic Cancer Diagnosis – a Nested Case Control Study in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
  4. International Survey on Diabetic Retinopathy.
  5. Meta-analysis on cardiovascular disease.
  6. Maher, T., Oballa, E., Simpson, J., Porte, J., Habgood,A., Fahy, W., Flynn, A.,  Molyneaux,P., Braybrooke, R., Divyateja, H. Parfrey, H., Rassl, D., Russell, AM., Saini, G., Renzoni, E., Duggan, AM.,  Hubbard, R., Wells, R., Lukey, P., Marshall,R., Jenkins, R.  Identification of an epithelial biomarker signature in Idiopathic Pulmonary Fibrosis: an analysis from the prospective multicentre PROFILE study.  Accepted for publication in The Lancet Respiratory Medicine.

Epidemiology and Real World

  1. Watson, L., Murphy, M., McCann, E. and Dillon R. Age and BMI changes in the HIV population of the UK (Submitted to International Journal of STD & AIDS).
  2. Watson, L., Mayes, A., Murphy, M., Dillon, R. and McCann, E. Comorbidity in the ageing HIV population of the UK: a longitudinal CPRD analysis (Submitted to HIV Medicine).
  3. Watson, L., Das, R., Farquhar, R., Langerman, H. and Barnett, A. H. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database. Curr Med Res Opin 2016 Feb 24:1-39.
  4. Das, R., Watson, L., Farquhar, R., Langerman, H. and Barnett AH. The impact of delaying treatment intensification in type 2 diabetes: Evidence from UK general practice. Diabetologia 2015 09;58(1): S347.
  5. Amber, V., Jameson, K., Das, R., Baxter, C. and Watson, L. A database analysis of patients eligible for second-line lipid-lowering treatment for hypercholesterolaemia in England. Value in Health. 2014. 17(7): A476-A477.
  6. Bushe, C., Wilson, B., Televantou, F., Belger, M. and Watson, L. Understanding the treatment of adult Attention Deficit Hyperactivity Disorder patients in general practice: A United Kingdom Database Study. Pragmatic and Observational Research 2015; 6: 1-12.
  7. Watson, L., Farquhar, R., Baxter, C. and Fuhat, A. Statin intolerance in patients from UK general practice: treatment and outcomes. In submission.
  8. Chrystyn, H., van der Palen, J., Sharma, R., Barnes, N., Delafont, B., Mahajan, A., Thomas, M. Device errors in asthma and COPD: systematic literature review and meta-analysis. Primary Care Respiratory Medicine (2017) 27:22.

Precision Medicine

  1. Flynn, A. Pharmacogenetics: practices and opportunities for study design and data analysis.  Drug Discovery Today 16, 19-20: 862-6. August 2011.
  2. Trusheim, M., Burgess, B., Hu, S. X., Long, T., Averbuch, S., Flynn, A., Lieftucht, A., Mazumder, A., Milloy, J., Shaw, P., Swank, D., Wang, J., Berndt, E., Goodsaid, F. & Palmer, M.  Quantifying factors for the success of stratified medicine.    Nature Reviews Drug Discovery 10, 817-833, November 2011, doi:10.1038/nrd3557
  3. Advances in Predictive, Preventive and Personalised Medicine. Vol 9 (2015) – Preventive and Predictive Genetics: Towards Personalised Medicine editors Godfrey Grech and Iris Grossman ISBN: 978-3-319-15343-8 (Print) 978-3-319-15344-5.
  4. Olazarán et al. A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer’s Disease. Journal of Alzheimer’s Disease 45 (2015) 1157–1173. DOI 10.3233/JAD-142925.
  5. Exploristics profile in Personalized Medicine, November 2015, Vol. 12, No.6, p537-540, doi 10.2217/pme.15.32.
  6. Jenkins, M., et al., A statistician’s perspective on biomarkers in drug development. Pharmaceutical Statistics 10; 6: 494-507. 2011, doi: 10.1002/pst.532.

Other Relevant Capabilities

  1. Denny F, Marshall A H, Stevenson M R, Hart P M, Chakravarthy U. Rasch Analysis of the Daily Living Tasks Dependent on Vision (DLTV). Invest Ophthamol Vis Sci, 2007; 48:1976 – 1982.
  2. Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Woodside JV, Denny F, MR Stevenson. Secondary Outcomes in a Clinical Trial of Carotenoids with Coantioxidants Versus Placebo in Early Age-Related Macular Degeneration. Ophthalmology, 2013; 120 (3): 600-606.